Biodistribution of [64Cu]Cu2+ and variance of metallothionein during tumor treatment by copper

Meixiang Yu, Huai Qing, Huang Guojian, Zhou Shu, Wang Wenqing, He Youfeng, Jyrki T. Kuikka

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

The kinetic distribution patterns of [64Cu]Cu2+ in normal mice and in mice bearing tumors (HepA, ascitic tumor) after i.v. injection were similar. The i.v. injected [64Cu]Cu2+ concentrated into mouse liver first and then went to other organs and tissues, such as kidney and tumor. Most of the [64Cu]Cu2+ injected concentrated into the liver within 4 h, and about 8% of the total [64Cu]Cu2+ injected concentrated into the tumor cells at 24 h after i.v. injection. About 80% and 90% of the soluble [64Cu]Cu in the livers of tumor-bearing mice and normal mice, respectively, existed as [64Cu]CuMT (metallothionein [MT] is a small protein with many cysteine residues) at 4 h after i.v. injection, while about 43% of the soluble [64Cu]Cu2+ in tumor cells combined with MT at 6 h after i.v. injection. After 10 days oral administration of 150 μg/g body weight copper acetate, the concentration of MT in tumor cells reduced sharply, from 316 μg/g tissue to 152 μg/g tissue, while it increased slightly, from 375 μg/g tissue to 439 μg/g tissue, in the livers of tumor-bearing mice (HepA, solid tumor). The results suggest that MT contributes to the metabolism of copper that is localized mainly in the liver after copper administration and that copper can concentrate into mouse tumor cells followed by the reduction of MT in tumor cells.

Original languageEnglish (US)
Pages (from-to)111-116
Number of pages6
JournalNuclear Medicine and Biology
Volume25
Issue number2
DOIs
StatePublished - Feb 1998

Keywords

  • Copper
  • Free radical
  • Kinetic distribution
  • Metallothionein
  • Tumor

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Biodistribution of [<sup>64</sup>Cu]Cu<sup>2+</sup> and variance of metallothionein during tumor treatment by copper'. Together they form a unique fingerprint.

Cite this